Azacitidine - Lonza/Lovelace Respiratory Research Institute
Alternative Names: 5-AZA - Lonza/Lovelace Respiratory Research Institute; 5-azacytidine - Lonza/Lovelace Respiratory Research Institute; inhaled 5-AZA dry powder - Lonza/Lovelace Respiratory Research InstituteLatest Information Update: 28 Jan 2025
At a glance
- Originator Lonza; Lovelace Respiratory Research Institute
- Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in Lung-cancer in Switzerland (Inhalation, Powder)
- 28 Jan 2025 No recent reports of development identified for research development in Lung-cancer in USA (Inhalation, Powder)
- 09 Dec 2020 Azacitidine - Lonza/Lovelace Respiratory Research Institute is available for licensing as of 09 Dec 2020. https://pharma.lonza.com/contact